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Health  Technology  Assessment  (HTA)  often  results  in  different  coverage  recommendations
across  countries  for  a  same  medicine  despite  similar  methodological  approaches.  This  paper
develops  and  pilots  a methodological  framework  that  systematically  identiﬁes  the  reasons
for these  differences  using  an  exploratory  sequential  mixed  methods  research  design.  The
study  countries  were  England,  Scotland,  Sweden  and  France.  The  methodological  frame-
work was  built  around  three  stages  of  the  HTA process:  (a)  evidence,  (b)  its  interpretation,
and  (c)  its inﬂuence  on  the  ﬁnal  recommendation;  and  was  applied  to  two orphan  medici-
nal  products.  The  criteria  accounted  for  at each  stage  were  qualitatively  analyzed  through
thematic analysis.  Piloting  the  framework  for two  medicines,  eight  trials,  43  clinical  end-
points  and  seven  economic  models  were  coded  155  times.  Eighteen  different  uncertainties
about  this  evidence  were  coded  28  times,  56%  of  which  pertained  to evidence  commonly
appraised  and  44%  to  evidence  considered  by only  some  agencies.  The  poor  agreement  in
interpreting  this  evidence  ( =  0.183)  was  partly  explained  by stakeholder  input (ns = 48
times),  or  by  agency-speciﬁc  risk  (nu =  28  uncertainties)  and  value  preferences  (noc =  62
“other  considerations”),  derived  through  correspondence  analysis.  Accounting  for variabil-
ity  at each  stage  of the  process  can  be  achieved  by  codifying  its existence  and  quantifying  its
impact  through  the  application  of  this  framework.  The  transferability  of  this  framework  to
other  disease  areas,  medicines  and  countries  is ensured  by its iterative  and  ﬂexible  nature,
and detailed  description.. Introduction
Health technology assessment (HTA) is widely adopted
o inform coverage decisions of medicines or health tech-
ologies by healthcare systems. It relies on evidence about
omparative effectiveness of alternative treatments in aPlease cite this article in press as: Nicod E, Kanavos P. D
work to systematically compare HTA coverage decision
http://dx.doi.org/10.1016/j.healthpol.2015.11.007
articular clinical setting and aims to ensure that those
overed provide value for money (or are cost-effective)
1], ultimately, improving access to medicines. In practice,
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countries frequently issue different coverage recommen-
dations despite appraising the same body of clinical
evidence and using similar methodological approaches.
These differences are inevitable due to the complexity of
these processes and the context within which they operate,
where each country sets its own objectives for conducting
HTA reﬂecting its values, preferences and constraints [2–4].
Implications include uneven access to these medicines
across (often neighbouring) countries, non-optimal use ofeveloping an evidence-based methodological frame-
s: A mixed methods study. Health Policy (2015),
healthcare resources, and the unpredictability of the phar-
maceutical market. Better understanding the application
of HTA in different settings and the reasons for diverg-
ing recommendations through cross-country learning and
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ealth PoARTICLEHEAP-3484; No. of Pages 11
2  E. Nicod, P. Kanavos / H
sharing of expertise is high on European and supra-national
agendas, and may  contribute to identify ways to minimize
these differences [5,6] or understand how innovation was
rewarded [7,8]. This is all the more important given the
recent appreciation of HTA as a means towards universal
healthcare [9] and the commitment of European Mem-
ber States in implementing cross-border HTA collaboration
through the EUnetHTA Joint Action 2.
Nine studies [10–18] compared HTA coverage recom-
mendations for medicines in more than one country and
identiﬁed important variations, where agreement ranged
from poor to moderate [10,11,13]. The countries compared
included Canada, Australia, England, Scotland, France,
New Zealand, and other European countries. One study
concluded that the most common reasons for differing rec-
ommendations related to the HTA process and context [10].
Another study highlighted cross-country variations for sev-
enteen of the most expensive medicines, but the extent of,
and reasons for these differences were not explored [12].
A more recent study investigated oncologic medicines,
where negative recommendations were largely due to the
high costs outweighing the marginal beneﬁts [14]. Possible
reasons for variations included differences in interpre-
ting the clinical endpoints or in levels of patient input,
or issues around appropriate comparators [14]. Another
study highlighted differences across therapy areas and
countries, suggesting that preferences varied according to
the therapy area being appraised [13]. These studies have in
common the qualitative approach adopted (retrospective
descriptive or cohort analyses) to identify these cross-
country variations, highlighting possible reasons for these
through single case study analyses. None, however, have
attempted to scrutinize these variations and query why
they occur in a systematic manner. This is likely due to
decision-making processes being complex with many fac-
tors being accounted for, which may  also be inter-related
and thus challenging to compare. Comparing these deci-
sion processes systematically could contribute to better
understanding the full range of factors accounted for and
determining the extent to which they explain differences
in coverage recommendations. Doing so would require a
methodological approach that decomposes these processes
to identify the key drivers contributing to decision-making
in a systematic way. While this approach may  not neces-
sarily eliminate the variation observed in the criteria used
to arrive at decisions, reducing it considerably would also
be beneﬁcial.
The aim of this study is to develop and pilot such a
methodological framework that allows for a compre-
hensive and systematic identiﬁcation and comparison
of the key factors that inﬂuence coverage decisions in
different stages of HTA processes.  A better understanding
of value assessment processes may  help address some
of the methodological challenges in conducting HTA and,
potentially, minimize cross-country differences when
these were a consequence of the review or interpretation
of the evidence.Please cite this article in press as: Nicod E, Kanavos P. D
work to systematically compare HTA coverage decision
http://dx.doi.org/10.1016/j.healthpol.2015.11.007
The framework proposed in this study is informed
by evidence from medicines with a European Medicines
Agency (EMA) orphan medicinal designation [19], which
have undergone an HTA in different settings in Europe. PRESS
licy xxx (2015) xxx–xxx
Orphan medicinal products are often characterized by sig-
niﬁcant inequalities in access [20] and are not always
cost-effective [21]. In this context, a broader range of fac-
tors are likely to be accounted for during the HTA process,
which are to be captured by the proposed framework.
2. Methods
2.1. Study design
A sequential exploratory mixed methods research
approach was  used to develop and pilot the methodolog-
ical framework in the form of an instrument development
design (Fig. 1) [23]. Both the depth and breadth of the
HTA decision process were captured within the qualitative
(stages I and II) and quantitative strands (stage III) [22,23].
A key characteristic of mixed methods design is the “itera-
tive and cyclic approach used in the research” [24], where
an inductive logic was used in the qualitative strand in
exploring and identifying the decision-making criteria, and
a deductive position was used to test the hypothesis made
by means of this framework in order to draw inferences
from the ﬁndings in the qualitative strand [25]. Priority
was  given to outline speciﬁcally the steps achieved in
designing and piloting this methodological framework,
while showcasing how the data collected can be analyzed
quantitatively without drawing any conclusions due to
the small sample size.
2.2. Sampling
Purposeful sampling was  used to select the study
countries with [27]: (a) well-established HTA agencies
and processes, (b) similar decision-making criteria (clin-
ical and/or cost-effectiveness), (c) adopting different
approaches in HTA (e.g. clinical beneﬁt versus clinical
cost-effectiveness assessment, health service versus soci-
etal approach), and (d) publicly available HTA reports. The
countries included were England, Scotland, Sweden and
France (Box 1).
Medicine and indication pairs were the unit of analysis.
The two case studies used to develop the proposed method-
ological framework were selected from all EMA  approved
orphan medicinal products – until December 2012 – and
appraised in the four study countries. Excluded were those
medicines that: (a) did not undergo the single technology
assessment process at NICE, or the full submission process
at SMC, and (b) did not receive diverging coverage rec-
ommendations. Coverage recommendations were either to
list, restrict or reject the medicine under review, or in the
case of France, to issue a ranking of clinical beneﬁt (Service
Médical Rendu, SMR) deﬁning the coverage decision and
rate, and one of improvement in clinical beneﬁt (Amélio-
ration du Service Médical Rendu, ASMR) providing a basis
for the price ﬁxing regime applicable, ranging from major
to insufﬁcient. For example, a medicine receiving an ASMR
V is considered not to provide any additional beneﬁt andeveloping an evidence-based methodological frame-
s: A mixed methods study. Health Policy (2015),
is covered only if its price is inferior or equal to the other
treatments available.
This resulted in the selection of two compounds:
eltrombopag (REVOLADE®) for the treatment idiopathic
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nal  stage.
hrombocytopenic purpura (ITP) and everolimus
AFINITOR®) as second-line treatment for advanced renal-
ell carcinoma (RCC) after failure of alternative therapies.
.3. Data sources and analysis
Stage I (qualitative strand) involved case studies used as
an intensive study of a single unit for the purpose of deﬁn-
ng a larger class of similar units” [29], to determine their
omparability across countries. Previous research aiming at
etter understanding HTA decision-making was also used
o outline the structure of the process [13]. Data sources
omprised HTA recommendation reports and other rele-
ant material published in the study countries and accessed
y the authors. Although these materials adopt similar
tructures and outline the rationale for the decision, their
urposes may  differ (e.g. legal document and memo  in
weden, summary of advice to the NHS in Scotland).
A case study template and coding manual were devel-Please cite this article in press as: Nicod E, Kanavos P. D
work to systematically compare HTA coverage decision
http://dx.doi.org/10.1016/j.healthpol.2015.11.007
ped. The case study template provides tables for the
nformation to be extracted and coded, to ensure it is
asily understandable and homogeneous across countries.
ach line item represents one criterion and the countriese stages of this mixed methods study aiming to simplify the complex
rces used to address the research questions and their integration in the
considering it, and includes identiﬁers to ensure cross-
country comparability. The coding manual exhaustively
lists all the criteria included in the case study templates,
organized into hierarchical levels clustered into common
themes, referred to as ﬁrst-order, second-order (clustering
ﬁrst-order themes) and third-order (clustering second-
order themes) themes (Appendix A).
Stage II (qualitative strand) aimed to systematically
capture the criteria accounted for during the HTA process
through thematic analysis [25] and determine the similar-
ities and differences across countries. Bottom-up coding
was undertaken for each HTA report [30], where codes
were created while examining the data to summarize and
categorize the criteria identiﬁed within the case studies.
The unit of coding, which is the section of text coded rep-
resenting one criterion, was  deﬁned and illustrated with
examples to avoid confusion or duplication in the results
[31]. Double-coding was performed to capture additional
information such as those cases where differences acrosseveloping an evidence-based methodological frame-
s: A mixed methods study. Health Policy (2015),
countries were seen, how these were dealt with, and
whether this inﬂuenced the ﬁnal decision. For exam-
ple, each uncertainty was double-coded with: (a) those
agencies that raised the same concern, (b) whether the
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uncertainty was addressed and by what means (e.g.
stakeholder input), and (c) whether it was one of the
main reasons for the ﬁnal outcome. Similar double-coding
was performed for the “other considerations” identiﬁed
(Appendix A).
Coding and clustering of codes were performed by the
lead author. Intra-coding reliability was tested to minimize
coding bias. Reliability of the clustering was tested by an
external person, who re-categorised each individual code
into one of these. Where differences were observed, adjust-
ments were made. An iterative approach was adopted
throughout the coding process to ensure that the iden-
tiﬁed criteria captured the numerous dimensions of the
decision-making process. At the end of the coding period,
all the information coded was reviewed to ensure that
the codes reﬂect what was meant to be coded (within
case-comparison) across all codes (cross-case comparison).
Primary data collection took place by means of the HTA
reports summarizing the recommendations and soliciting
input from HTA experts and HTA body representatives to
obtain additional insights about the decisions and ensure
that the criteria were coded accurately. The analysis was
performed using QSR International’s NVivo10 [32].
In stage III, codes were quantitatively analyzed both
vertically and horizontally through descriptive exploratory
analyses [30] to study their interrelationships. Thematic-
matrixes summarizing the codes per medicine and country
were exported from NVivo10 into Excel and transformed
into nominal variables. The statistical software STATA13
was used for the analysis [33]. The vertical dimension
provided ﬁndings about agency-speciﬁc risk and value
preferences. “Risk” was derived from the concerns of the
HTA bodies pertaining to uncertainty, and “value” from
the “other considerations” relating to the disease and
treatment characteristics accounted for. Preferences were
explored through correspondence analysis, where the
associations between the variables (HTA bodies versus
uncertainty or “other considerations”) were measured and
illustrated in correspondence analysis biplots [35,36]. The
horizontal dimension provided a measure of agreement
between the HTA bodies in interpreting the same evidence
using Cohen’s kappa scores [37], allowing for a more
robust evaluation of qualitative ﬁndings by comparing
observed frequency of agreement with the probability of
agreement occurring by chance.
2.4. Study limitations
Whereas the objective of this study is to develop and
pilot a framework, which would then be applicable to a
wider sample of medicines because of its iterative nature,
it is not without limitations. One limitation is whether spe-
ciﬁc aspects of the decision-making process, particularly
the context within which a decision was made, were cap-
tured; these contextual considerations, however, were not
within the scope of this study. A second limitation relates to
the purpose and level of detail provided in the HTA reports,Please cite this article in press as: Nicod E, Kanavos P. D
work to systematically compare HTA coverage decision
http://dx.doi.org/10.1016/j.healthpol.2015.11.007
which varies by country. This is unlikely to have affected
the results given that the key determinants, deﬁned as
the main reasons for the ﬁnal recommendations, were
included in all the reports and provide a good overview PRESS
licy xxx (2015) xxx–xxx
of the decision criteria; data triangulation ensured sufﬁ-
cient detail was  captured in each case, and comprised the
HTA reports, other material and case studies, input from
HTA experts (e.g. Advance-HTA consortium, conferences),
and interviews with HTA bodies where ﬁndings were pre-
sented and feedback collected. A third limitation is that the
framework relies on two case studies. However, these were
selected to proxy decision frameworks in orphan oncology
and non-oncology treatments because the ways of valuing
these may  differ. The two cases are very different in terms
of both disease and treatment characteristics, and therefore
are considered to appropriately cover different dimensions
of decision processes. Finally, the transferability of this
framework to other countries and therapy areas is limited
to those cases where similar decision-making criteria are
accounted for, from HTA entities that are arm’s length,
responsible for issuing coverage recommendations, and
have a transparent process where sufﬁcient detail about
the appraisal process and reasons for the ﬁnal decision are
recorded in their decision reports.
3. Findings
The ﬁrst two sections (qualitative strand) outline the
information collected and coded based on the case study
template, showcasing how the proposed structure was
used to set up and pilot the methodological framework.
Section 3.3 showcases how the data collected can be quan-
titatively analyzed, where the case studies were used as
illustrative examples and results are by no means general-
izable due to the small sample.
3.1. Qualitative strand: Developing the methodological
framework
The structure of the methodological framework was
based on the three key stages of the decision-making
process identiﬁed: (a) the clinical and cost-effectiveness
evidence, comprising clinical trials and endpoints, safety,
economic models, and comparators, (b) the interpretation
of this evidence, relating to uncertainty, “other consid-
erations” and stakeholder input, and (c) the ﬁnal HTA
recommendation, and how the previous two stages inﬂu-
enced the recommendation formulation (Fig. 2). These
criteria formed the basis for the case study template and
coding manual, both tools forming the methodological
framework (Appendix A).
3.2. Qualitative strand: Testing the methodological
framework
Eltrombopag and everolimus received diverging HTA
recommendations for the treatment of ITP and RCC, respec-
tively. Eltrombopag was rejected in England, restricted in
Scotland to patients with severe symptomatic ITP or a
high risk of bleeding, and listed in Sweden until its re-
assessment in 2 years’ time. In France, it was valued as hav-eveloping an evidence-based methodological frame-
s: A mixed methods study. Health Policy (2015),
tant improvement in medical beneﬁt (ASMR II). Everolimus
was  rejected in England and Scotland, listed as applied for
in Sweden, and considered to provide an important medical
beneﬁt in France with a low added beneﬁt (ASMR IV).
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cig. 2. Methodological framework for the systematic comparison of HTA
ethodological framework, together with the outcomes from quantitativ
nd  horizontally (e.g. when differences at each stage of the process expla
.2.1. Clinical and cost effectiveness evidence
The same phase III primary trials were considered
or both medicines. Additional trials were considered for
ltrombopag, one of which was an indirect compari-
on with romiplostim appraised by all except HAS. For
verolimus, subgroup analyses of the primary trial by pro-
nostic categories were also considered by SMC  and HAS,
hereas NICE additionally conducted a meta-analysis of 28
tudies (Table 1).
The clinical endpoints from the same trials were
eported in a variety of ways (Table 1). For example, WHO
–4 bleeding events were only recorded for eltrombopag
y NICE, and health-related quality of life (HRQoL) relied on
he number of domains reported, where it was signiﬁcant
ver four (as reported by SMC) but not over six domains (as
eported by NICE). Results from indirect comparisons were
tatistically signiﬁcant across the whole population, but
ot signiﬁcant when considering only patient subgroups
as reported only by NICE). A similar scenario was  seen
or everolimus, where HRQoL was not reported by TLV
nd neither were objective response rate or progression-
ree survival from the subgroup analysis by NICE or TLV.
dverse events were reported by all agencies except TLV,
ut this can be explained by the difference in purpose
f the TLV reports, which are of legal nature. The most
ommon and clinically signiﬁcant adverse events and treat-
ent discontinuation rates were reported homogeneously.
AS usually provided more detail about the percentage of
atients affected and deaths (even if not associated with
he treatment).Please cite this article in press as: Nicod E, Kanavos P. D
work to systematically compare HTA coverage decision
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The clinical evidence identiﬁed included: (a) the clini-
al trials, comprising eight trials (three primary trials) and
ve subgroup analyses with their respective comparators,
oded 51 times across countries; (b) 43 different clinicalses. Illustrates the three key stages identiﬁed and used as a basis for the
ysing the data collected both vertically (e.g. agency-speciﬁc preferences)
erences in HTA recommendations across countries).
endpoints coded 68 times, and (c) the assessment of safety,
recorded in a variety of ways and coded 22 times. This
resulted in a total of 141 codes each representing an
individual criterion. For example, each trial was coded
according to the type of trial (e.g. phase III, phase II),
the type of comparator (e.g. placebo, standard care), and
whether it was a primary trial.
Economic models were considered by all HTA agen-
cies except HAS. Those considered for eltrombopag differed
from the comparator and/or type of model considered. NICE
appraised three models with different comparators: (1)
“watch and rescue”, (2) romiplostim, and (3) a sequence
of treatments. The watch and rescue model was consid-
ered the most appropriate (reﬂecting clinical practice), and
the other two were rejected on the basis that they do
not represent clinical practice (romiplostim at the time
was under review at NICE), or were not valid, respectively.
In contrast, SMC  considered a cost-utility model compar-
ing eltrombopag to romiplostim in splenectomised and
non-splenectomised patients, and TLV a cost-minimization
analysis with the same comparator based on a non-
inferiority claim. For everolimus, the same cost-utility
models were considered. This resulted in a cost per QALY
ranging from £49,000 to £51,700 for NICE, £61,330 for
SMC, and was  not speciﬁed in TLV’s HTA report. The cost-
effectiveness evidence consisted in the economic model
and its comparator, both coded 7 times (Appendix A).
3.2.2. Interpretation of the evidence
A total cumulative number of 18 clinical uncertaintieseveloping an evidence-based methodological frame-
s: A mixed methods study. Health Policy (2015),
were raised by the agencies (10 for eltrombopag and 8 for
everolimus), coded 28 times (as some may  have been raised
by more than one agency) (Table 2). 56% (of 18 uncertain-
ties) were based on evidence commonly appraised by all,
ARTICLE IN PRESSG ModelHEAP-3484; No. of Pages 11
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Table 1
Clinical trials and their endpoints considered for eltrombopag and everolimus (non-exhaustive list).
Eltrombopag England NICE Scotland SMC  Sweden TLV France HAS
RAISE Phase III, 6-month,
placebo-controlled
(N = 197)
Platelet response
√ √ √ √
Primary endpoint
Rescue treatment
√ √ √
Bleeding (WHO1-4)
√ √ √ √
Bleeding (WHO2-4)
√ √ √
Clinically signiﬁcant bleeding
Bleeding (WHO3-4) × Gross (grade 3) and debilitating
(grade 4) blood loss
Main  reduction in bleeding × √ Seen in grade WHO2
HRQOL (SF36)
√
4
×6
√
4 Signiﬁcant over 4 domains, and
not over 6
KUTER Indirect comparison
with RAISE
Platelet response
√
NR NR NA Primary endpoint
Platelet response × Splenectomised patients
Platelet response × Non-splenectomised patients
Everolimus
RECORD-1 Phase III,
placebo-controlled
(N = 416)
Progression-free survival
√ √ √ √
Primary endpoint
Overall survival × × × × Blinded phase
HRQOL R* ×* ×** *EORTC, FKSI-DRS
**QLQ-C30
Objective response × ×
Progression-free survival
(subgroup analysis)
√ √
Per risk stratiﬁcation group
NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Beneﬁts Board; HAS:
Haute  Autorité de Santé;
√
: Statistically signiﬁcant; ×: Non-statistically signiﬁcant; R: reported; NR: not reported; NA: not applicable; EORTC: European
ssessm
 the disOrganisation for Research and Treatment of Cancer; FKSI-DRS: Functional A
QLQ-C30: quality of life questionnaire and the symptoms associated with
while the remaining 44% on evidence included in only some
of the appraisal reports. 38% (of 18 uncertainties) were also
put forward as one of the main reasons for the ﬁnal recom-
mendation.
Table 2 illustrates the different phases in interpreting
the clinical evidence. The ﬁrst column (e.g. evidence, con-
sidered by) reports, per agency, the evidence interpreted
and whether it was primary evidence. The second col-
umn  (e.g. interpretation, raised by) reports cases when this
evidence was considered uncertain, and whether it was
nevertheless deemed acceptable or not (e.g. addressed or
not). The last column (e.g. outcome, main reason for rec-
ommendation) reports cases when this issue was also one
of the main reasons put forward for the ﬁnal recommen-
dation.
This allowed to understand how these issues were dealt
with across settings. For example in the case of eltrom-
bopag, the lack of direct comparative data was generally
a concern and one of the main reasons for the ﬁnal rec-
ommendation for TLV and HAS, and the primary trial’s
small sample size was a concern only for TLV, but con-
sidered acceptable given the treatment’s orphan status.
Another example is NICE’s concern that no improvement
was seen in the lower incidence of the most severe bleed-Please cite this article in press as: Nicod E, Kanavos P. D
work to systematically compare HTA coverage decision
http://dx.doi.org/10.1016/j.healthpol.2015.11.007
ing events (WHO grades 3 and 4); this issue was  not raised
nor recorded by the other agencies either because the end-
point was not speciﬁcally appraised or was not identiﬁed
as being relevant to the decision. In the case of everolimus,ent of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms;
ease; Primary endpoint in bold.
the primary trial was  terminated early due to the superior
efﬁcacy stopping rule, and results were biased due to
cross-overs (81% of patients). Nevertheless, overall survival
estimates were deemed plausible for NICE based on clini-
cal expertise and results from a meta-analysis, and for SMC
and TLV based on a speciﬁc tool used to derive these esti-
mates. In contrast for HAS, no beneﬁt was  demonstrated
(Table 2).
A similar analysis about the interpretation of the eco-
nomic models is possible in order to understand the types
of concerns raised by each HTA body, how these are compa-
rable and dealt with. For example, the model appraised by
NICE was  considered highly uncertain and driven by costs
rather than beneﬁt. One of the main concerns was about
the assumption that differences in treatment arise because
of bleeding events, which was used as the main effective-
ness endpoint despite platelet response being the trial’s
primary endpoint. SMC  was  also concerned about the rela-
tive risk of bleeding events, but with a different comparator
(romiplostim).
A number of “other considerations” were identiﬁed in
the HTA reports and coded 62 times, differentiated by
whether they pertained to the treatment (e.g. type of ben-
eﬁt, innovativeness) or to the disease (e.g. severity, unmeteveloping an evidence-based methodological frame-
s: A mixed methods study. Health Policy (2015),
need) (Table 3). These may  have been put forward as part
of the reasoning for the ﬁnal recommendation and/or may
have been raised by different stakeholders (e.g. patients,
clinicians). For instance, the oral administration beneﬁt of
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Table 2
Differences and similarities in the interpretation of the clinical evidence and main reasons for recommendation.
Evidence considered by Interpretation uncertainty raised by Outcome main reason for recommendation
√
Evidence considered
√
*evidence
considered within the pivotal trial
√
Positive inﬂuence
(addressed)
× Negative inﬂuence
(not addressed)
√
Positive inﬂuence
(addressed)
× Negative inﬂuence
(not addressed)
Clinical uncertainties England
NICE
Scotland
SMC
Sweden
TLV
France
HAS
England
NICE
Scotland
SMC
Sweden
TLV
France
HAS
England
NICE
Scotland
SMC
Sweden
TLV
France
HAS
Eltrombopag Lack of comparator
√
*
√
*
√
*
√
* × × × × × ×
Short  duration of trial
√
*
√
*
√
*
√
* × × × ×
Sample size
√
*
√
*
√
*
√
*
√ √
Trial  population, indication under
review
√
*
√
*
√
*
√
*  × ×
Trial  population, generalizability
√
*
√
*
√
*
√
*
√ ×
Trial population, low platelet count
patients instead of those with severe
risk of bleeding
√
*
√
*
√
*
√
*
√
Signiﬁcant bleeding events (WHO3-4)
√
* × ×
Quality of life estimate
√ √ × ×
Liver  function monitoring
√ ×
Uncertain nature of the indirect
comparison
√ √√ √ × ×
Everolimus Bias  in overall survival (cross-overs)
√
*
√
*
√
*
√
*
√ √ √ √ √ √ √ ×
Weak  overall and partial response
√
*
√
* ×
Lack  of comparative safety evidence
√ √ √ √ ×
Trial population, patients with
co-morbidities excluded
√
*
√
*
√
*
√
* ×
Trial  population, generalizability
√
*
√
*
√
*
√
*
√
Risk  of pneumonitis,
immunosuppression
√ √ √ √ √
Quality of life estimate
√ √ √ ×
Risk stratiﬁcation method not
applicable (subgroup analysis)
√ √ √ ×
NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Beneﬁts Board; HAS: Haute Autorité de Santé.
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Table 3
“Other considerations” identiﬁed in the HTA reports.
Eltrombopag Everolimus
Subcategory Illustrative quotations/code England NICE Scotland
SMC
Sweden
TLV
France
HAS
England NICE Scotland
SMC
Sweden
TLV
France
HAS
Treatment
characteristics
Type of beneﬁt Curative, life-extending
√ √
End-of-life
√
Innovativeness Innovative, new class of drugs
√
Clinicians
√
Main
√
Clinicians/patients
Adverse effects Similar across treatment arms
√
Patients willing to cope, manageable, tolerated,
transient, reversible
√
Patients
Administration Oral administration
√
Main
√
Main
Disease
characteristics
Unmet need Unmet need, no treatment alternatives, few
alternatives, need for treatment options
√
Clinicians
√
Main
√
Main
√ √
Clinicians/patients
√
Nature of the
condition
Disease severity, serious condition
√
Main
√ √
Main
Life-threatening
√
Clinicians/patients
√
Main
√
Clinicians/patients/
End-of-life
√ √
Short  life-expectancy
√
End-of-life
√
Impact on quality of life, functional capacity,
impact on daily activities
√
Clinicians/patients
√
Main
√
Social stigma, limiting of life-style choices,
ability to work, travel or undertake leisure
activities, limiting life-style choices
√
Clinicians/patients
Rare disease Orphan status, small population, rarity
√
Main
√
Main
√ √
Clinical
practice
No  routine standard pathway, complex clinical
practice, tailored to the patient
√
Clinicians
√
Clini-
cians
Comparator unlicensed for indication, and
associated with important adverse events and
anxiety
√
Clinicians/patients
No long term evidence and unknown correct
dosage of comparator
√
Clinicians
Later diagnosis when disease advanced
√
Licensed over non-licensed preferred
√
Clinicians
National
priority
Plan Maladies Rares (2004)
√
NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium; TLV: Dental and Pharmaceutical Beneﬁts Board; HAS: Haute Autorité de Santé; Main: considered one of the main
reason  for the ﬁnal recommendation; X: considered during the assessment; Clinicians: put forward by clinicians; Patients: put forward by patients; End-of-life: eligible as “end-of-life treatment” for NICE.
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ltrombopag was one of the main reasons for the ﬁnal
ecision by SMC  and TLV, patients and clinicians stated
hat adverse events are tolerable and manageable, and that
atients are willing to cope with them in order to get treat-
ent. Another example is the life-threatening nature of the
ondition that was put forward by patients and clinicians
n the NICE appraisal for everolimus, and was also one of
he criteria for recognising the treatment as an end-of-life
reatment.
Stakeholder input was identiﬁed 46 times in the NICE
eports and twice in the SMC  reports; none was iden-
iﬁed for TLV or HAS. For NICE, patient input providing
nformation about “other considerations” (e.g. impact on
aily activities) was seen in 30% of cases (14 out of 46),
nd clinical input about “other considerations” (e.g. limited
reatment options) or commenting on clinical and eco-
omic uncertainties (e.g. clinical practice) was seen in
0% of cases (32 out of 46). For SMC, clinical experts
rovided input about “other considerations” (e.g. clinical
ractice) and commented on uncertainty (e.g. generaliz-
bility) (Table 3).
.3. Quantitative strand (Stage III): Outcomes from the
ethodological framework
.3.1. Clinical evidence and its interpretation
Reasons for differing HTA recommendations include
nstances when different evidence was considered, or
hen the same evidence was interpreted differently.
able 2 illustrates cases when uncertainties were raised
ased on different clinical evidence. For example, HAS was
oncerned about the lack of HRQoL data given the impact
f the disease on the patient. This was not an issue for NICE
nd SMC  since it was included in the assessment.
When considering the same evidence, agreement was
oor using Cohen’s kappa scores ( = 0.183, 95% CI [0.015;
.35]) [38]. These differences may  relate to a subjective
unexplained) component of the decision or to differ-
nt risk or value preferences. Risk preferences, when one
gency is relatively more likely to raise a concern when
ppraising the same evidence compared to the other agen-
ies, were identiﬁed through correspondence analysis.
lthough the chi-squared probability of independence was
on-signiﬁcant given the small sample size (2 = 22.49;
 = 0.550), the results nevertheless provide an indication
f the relationships among these variables as well as
he type of analysis that this framework allows for on a
reater sample, illustrated in the correspondence analy-
is biplot (Appendix B). Similarly, value preferences were
erived from the “other considerations” identiﬁed through
orrespondence analysis, and revealed a signiﬁcant asso-
iation in terms of the relative value preferences for
hese two medicines (2 = 30.97; p = 0.029) (Appendix C).
ne example illustrating how preferences inﬂuenced the
cceptability of an uncertainty was for eltrombopag, where
he small sample size was  deemed acceptable for TLV given
ts orphan status (Tables 2 and 3, Appendixes B and C).Please cite this article in press as: Nicod E, Kanavos P. D
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.3.2. Criteria driving the decisions
The criteria that drove the HTA decision-making pro-
ess consist of the main reasons for the recommendation PRESS
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identiﬁed at each stage of the process (Tables 2 and 3),
potentially inﬂuenced by agency-speciﬁc risk or value
preferences or because of the subjectivity in the interpreta-
tion of the results (measured by agreement levels), which
resulted into the following decisions.
Eltrombopag was  rejected by NICE mainly because of
the high uncertainty that increased the ICER to a level
greater than what is considered cost-effective. For SMC,
although the clinical evidence was weak, eltrombopag
was signiﬁcantly more effective than placebo in platelet
response and considered cost-effective, as greater uncer-
tainty in the economic analysis was accepted because it
offers additional treatment options, is an orphan medicinal
product, and is administered orally. For TLV, eltrombopag
was considered cost-effective because of its similar effect at
a lower cost compared to romiplostim, which had already
been considered as cost-effective by the TLV. The orphan
status, severity of the condition, and impact on the patient’s
HRQoL were also put forward, with a follow-up of effective-
ness to take place in October 2013. For HAS, while the trial
duration was limited and comparative data was lacking,
eltrombopag was  considered similar to romiplostim until
further evidence is provided (risk assessment plan).
Because of the early termination of the trial, the esti-
mated clinical beneﬁt of everolimus was considered biased.
For NICE, overall survival was  considered superior to 3
months and the treatment was eligible as “end-of-life treat-
ment”. Despite this, sensitivity analysis showed only a
very low probability of the medicine being cost-effective
and was rejected. For SMC, the price was  considered too
high in comparison with the positive beneﬁts provided. In
Sweden, the high cost per QALY was  acceptable given the
disease’s severity. In France, despite being a serious and
life-threatening condition, the evidence presented was not
sufﬁcient to demonstrate any improvement in survival or
HRQoL relative to alternatives.
4. Discussion and policy implications
4.1. Summary of key results
This empirical study ﬁtted a mixed methods research
design to a research question requiring both an in-depth
understanding of the HTA decision-making process and
a systematic approach to comparing cases in order to
gain a broader understanding of the HTA outcome. The
case study analyses highlighted the complexity of these
decisions and identiﬁed a structure facilitating the under-
standing and comparability of these processes. This was
used to derive and pilot the methodological framework,
which divided the decision-making process into three
stages within which a set of criteria were identiﬁed and
coded. This enabled to identify the criteria driving decision
processes and explaining cross-country differences.
4.2. How do our ﬁndings ﬁt with existing evidence?eveloping an evidence-based methodological frame-
s: A mixed methods study. Health Policy (2015),
Comparing our results with existing studies that inves-
tigated the criteria inﬂuencing HTA decisions in at least
one of the study countries (corresponding to the verti-
cal dimension of this study), two studies were identiﬁed
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and their ﬁndings are consistent with ours. One review of
quantitative studies identiﬁed existing empirical evidence
about coverage decisions for a range of health technologies
[39]. Despite not being directly comparable with our study
given it included all types of technologies, it is of inter-
est to ensure that the components of HTA included in our
study are comprehensive. Carroll et al. conducted a the-
matic analysis of the assessments of medicines made by
the Evidence Review Group (ERG) at NICE to identify the
strengths and weaknesses in the submissions [40]. Even
though it is again not directly comparable to our study, it
remains of interest since it is accounted for by NICE and cor-
responds to the “interpretation of the evidence” stage in our
study. Findings from these two studies validate our classi-
ﬁcation of the decision-making criteria and conﬁrm that
our results are appropriate and comprehensive. Focusing
on the horizontal dimension included in our framework,
only few comparative studies of HTA decisions exist, as
reported in the introduction section. None, however, have
compared the decision-making processes in a systematic
manner.
4.3. The methodological framework
The added-value of this study is by deconstructing HTA
recommendations and developing a taxonomy of criteria
that may  have contributed to the decision-making process,
it enables an enhanced understanding of HTA decision-
making [41]. Without a mixed methods study design, we
would not have been able to capture the depth and com-
plexity of these decision-making processes, both within
and across countries. The novelty of this methodological
framework lies, ﬁrst, in the systematic approach adopted
in analysing the data, and, second, in the inclusion of a hor-
izontal dimension to capture additional aspects of the HTA
decisions. The coding and categorization of HTA documents
enabled a systematic identiﬁcation of the decision-making
criteria in a homogeneous and comparable manner across
countries and medicines. Further, the horizontal dimen-
sion also captured, through double-coding, the inﬂuence
(“positive” or “negative”) of each criterion on the ﬁnal deci-
sion (“main reason for recommendation”) and whether it
was provided through stakeholder input. Finally, this study
exempliﬁes how this type of design can be implemented
to ﬁt a speciﬁc research question and disseminated in a
clear and transparent manner. It also highlights the inter-
disciplinary potential of applying such designs to novel
areas, such as HTA.
4.4. Policy implications
Based on its application to two cases, results show that
a signiﬁcant number of additional criteria and consider-
ations may  be used to inform decisions, which may  override
pre-existing rules, such as an ICER threshold. This was a
consequence of the heterogeneity seen in the evidence
and its interpretation, or of additional criteria or input,Please cite this article in press as: Nicod E, Kanavos P. D
work to systematically compare HTA coverage decision
http://dx.doi.org/10.1016/j.healthpol.2015.11.007
which may  have inﬂuenced the decision. This may  be due,
in part, to the orphan nature of these medicines, where
accounting for “other considerations” may  overcome some
of the uncertainty characterising the evidence generated PRESS
licy xxx (2015) xxx–xxx
from small patient populations. It may  also be interpreted
either as a need to examine in greater depth the avail-
able evidence on speciﬁc medicine-indication pairs rather
than stick to a yes–no decision based on otherwise inﬂex-
ible rules, or as a recognition of the imperfect nature of
the HTA process to account for detailed information that
may  matter when making a decision at the margin, or a
combination of both. Results from applying this framework
also allow to raise awareness on the reasons for cross-
country differences. When differences were a consequence
of the review, the interpretation of the evidence and deal-
ing with uncertainty, it may  contribute to ﬁnding solutions
to minimising these differences. When applied across a
greater sample of medicines, therapy areas and countries,
the application of this framework may  be beneﬁcial in a
variety of ways: to identify decision-making criteria that
can feed into other types of models (e.g. MCDA), to iden-
tify agency-speciﬁc preferences, to understand the type of
stakeholder input meaningful to provide, or to ensure con-
sistency in the “other considerations” accounted for (e.g.
accountability for reasonableness).
5. Conclusion
Improving the level of access to medicines is a pri-
ority at both European and supra-national levels [7,8].
The substantial variations seen in HTA recommendations
is one of the causes of differential access to medicines
and possibly reﬂects weaknesses in HTA methodologies,
where the implications are enormous in seeking to obtain
value for money. The urgent need to better understand
the reasons for variations in decision-making processes
and improve the quality of assessments is recognized. In
this study, we  have proposed, developed and piloted a
methodological framework aiming to account for (part
of) the unexplained heterogeneity in HTA recommen-
dations across settings. The framework is detailed and
provides insights into decision-making practices in the case
studies concerned. The framework’s external validity is
currently being enhanced and applied to a larger sample
of medicines, therapy areas and countries.
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